Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Analysts and calls -- A.G. Edwards -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1)	10/14/2002 4:52:38 PM
From: JFitnich	Read Replies (1) \| Respond to of 6

As of 9-20-02 : 3 tier rating system - Buy, Hold, Sell With a Risk Suitability component - Conservative, Aggressive, Speculative The calls: AMGN - Buy / Speculative BGEN -- Buy / Speculative CHIR - Buy / Speculative DNA - Buy / Speculative ABGX - Buy / Speculative CATG - Buy / Speculative CRGN - Hold / Speculative HGSI - Buy / Speculative ("favorite genomics firm") INCY - Hold / Speculative ("firm in transition" & "may be too little too late to shift business model back to drug making" as customers have had years to cull the database) MLNM - Hold / Speculative (risk of dilutive deal to reach '04 profit guidance) They strongly suggest buying gene therapy companies as part of a "basket" AVGN - Buy / Speculative GNVC - Buy / Speculative ONXX - Buy / Speculative TGEN - N/A Info only (??) ("serious danger of running out of money") VCAL - Hold / Speculative They have price objectives (9-20-02)of : $10 - GNVC, ONXX $12 - ABGX & CATG, $13 - AVGN $22 - HGSI $35 - DNA $40 - BGEN, CHIR $50 - AMGN They've had a major HGSI "jones" for awhile now. They don't really hit on the science as much as they do the fundamentals. They are good at seeing the big picture and fundamental analysis IMO. JF